ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
Key Highlights
- ➤Duloxetine delayed-release capsules launched in 20, 30, and 60 mg strengths
- ➤Duloxetine generic addresses a limited-player market and supports stable supply
- ➤U.S. annual duloxetine sales totaled approximately $247 million through August 2026
- ➤ANI Pharmaceuticals (ANIP) launched generic Cymbalta capsules for U.S. patients
Expert Statements
Nikhil Lalwani, President and Chief Executive Officer of ANI Pharmaceuticals
“By launching Duloxetine Delayed-Release Capsules, ANI is providing another alternative of a widely used therapy in a limited player market to assure stable supply. Through close customer and manufacturer partnerships and a focused regulatory effort, we are proud to make this important and widely used therapy available to patients and providers.”
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta(®).
“By launching Duloxetine Delayed-Release Capsules, ANI is providing another alternative of a widely used therapy in a limited player market to assure stable supply. Through close customer and manufacturer partnerships and a focused regulatory effort, we are proud to make this important and widely used therapy available to patients and providers,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
Get started
Create a free account to read the full story.